Integer Holdings Corp — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Integer Holdings reported Q3 2026 sales of $450M (down 3.9% YoY, -2.2% organic), with GAAP operating income falling 50% to $28M and adjusted EBITDA declining 17% to $88M. The company received HSR early termination on September 29, 2026, and stockholder approval on October 21, 2026, for KKR's acquisition (Merger Agreement dated August 2, 2026); transaction expected to close by end of 2026. Total debt increased $34M to $1.219B; leverage ratio 3.3x adjusted EBITDA. Cardio Vascular sales fell 5% to $263M (new product headwinds); Cardiac Rhythm Management rose 4% to $176M; Other Markets down 49.7% to $11M (Portable Medical exit).
Why this rating
Modest organic sales decline and margin compression are concerning but typical for CDMO; KKR deal is transformational event but already announced. No new material catalyst; execution risk remains on deal close and product ramp.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.